We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

Merck has a broader product portfolio with more than 52 drugs ... Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

When a pharmaceutical company such as Merck has an extremely successful product such as Keytruda, it can be both a blessing and a curse. Keytruda is a significant source of revenue growth for the ...

We recently published a list of 10 Best Healthcare Stocks ... and animal health products. At its core, Merck is in the business of improving human and animal health through scientific innovation.

Merck has secured the option to license the vaccines for up to $10 million next year. If the drugmaker takes up that option, Evaxion will be in line to receive up to $592 million per product.

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from ... known as MMR-II, and another product called ProQuad that additionally protects against varicella, also known as chickenpox.